IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.575
EU - Europa 2.614
AS - Asia 1.270
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 10
AF - Africa 9
OC - Oceania 2
Totale 7.491
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.564
IE - Irlanda 668
IT - Italia 514
SG - Singapore 492
CN - Cina 427
SE - Svezia 420
UA - Ucraina 261
FR - Francia 205
TR - Turchia 171
GB - Regno Unito 152
DE - Germania 142
IN - India 110
RU - Federazione Russa 87
FI - Finlandia 49
VN - Vietnam 48
BE - Belgio 42
CZ - Repubblica Ceca 18
AT - Austria 12
EU - Europa 11
PL - Polonia 11
CA - Canada 9
HK - Hong Kong 6
RO - Romania 6
BR - Brasile 5
EG - Egitto 5
GR - Grecia 5
JP - Giappone 5
ES - Italia 4
LT - Lituania 4
PT - Portogallo 4
NL - Olanda 3
PK - Pakistan 3
CL - Cile 2
CO - Colombia 2
ID - Indonesia 2
MA - Marocco 2
TW - Taiwan 2
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
DZ - Algeria 1
IR - Iran 1
KR - Corea 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
MX - Messico 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 7.491
Salva come PNG Salva come JPEG
Città #
Chandler 877
Dublin 644
Jacksonville 446
Singapore 412
Princeton 262
Ashburn 181
Nanjing 124
Chieti 116
Izmir 112
Dearborn 105
Wilmington 105
Southend 104
Altamura 100
Santa Clara 93
Beijing 91
Ann Arbor 89
Boardman 57
Los Angeles 56
Cambridge 53
New York 48
Dong Ket 47
Brussels 41
Washington 39
Menlo Park 36
Nanchang 30
Munich 25
Shenyang 24
Norwalk 21
Falls Church 19
Hebei 19
Woodbridge 19
Kunming 18
Pescara 18
Rome 18
Tianjin 16
Houston 15
Seattle 15
Jiaxing 13
Hangzhou 12
Vienna 12
Brno 11
Milan 11
Edinburgh 10
Helsinki 10
Pune 9
Redwood City 9
Grevenbroich 8
Kraków 8
Changchun 7
Hefei 7
Guangzhou 6
Hong Kong 6
London 6
Mcallen 6
Ascoli Piceno 5
Cairo 5
Changsha 5
Giaveno 5
Lanciano 5
Moscow 5
Pisa 5
Simi Valley 5
Tappahannock 5
Tokyo 5
L’Aquila 4
Madrid 4
Rouen 4
Shanghai 4
Altino 3
Ameno 3
Amsterdam 3
Aprilia 3
Athens 3
Bangalore 3
Garden City 3
Islamabad 3
Jinan 3
Lanzhou 3
Montreal 3
Olomouc 3
Ottawa 3
Paris 3
Perego 3
Prague 3
Redmond 3
San Mateo 3
Sulmona 3
Tucson 3
Andover 2
Antrodoco 2
Bari 2
Bogotá 2
Bordeaux 2
Boston 2
Chengdu 2
Chicago 2
Chongqing 2
Collecorvino 2
Fairfield 2
Frankfurt am Main 2
Totale 4.796
Salva come PNG Salva come JPEG
Nome #
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 117
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 111
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 111
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 109
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 100
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 98
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 97
New Targets for Therapy in Pancreatic Cancer 94
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 93
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 92
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 91
null 90
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 89
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 88
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 88
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 88
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 86
Principali effetti collaterali delle terapie mediche 86
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 86
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 86
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 85
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 83
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 82
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 81
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 81
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 81
Speed rate (SR) as a new dynamic index of melanoma behavior 79
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 78
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 78
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 77
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 77
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 76
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 74
Rivaroxaban for cancer-associated cardiac thrombosis 74
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 73
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 72
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 72
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 72
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 72
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 72
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 70
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 70
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 70
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 69
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 69
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 68
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 67
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 67
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 67
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 67
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 66
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 66
null 65
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 65
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 65
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 65
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 64
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 64
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 64
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 64
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 63
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 63
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 62
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 62
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 62
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 61
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 61
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 61
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 60
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 60
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 59
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 59
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 59
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 58
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 57
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 56
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 55
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 55
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 55
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 55
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. 54
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 54
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 54
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 53
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 53
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 53
Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP) 52
Nivolumab and diabetes mellitus: safe administration in a patient with pancreatic metastases from melanoma 52
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 52
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 51
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 51
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 50
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 49
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 49
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 49
Poor risk metastatic renal cell carcinoma (mRCC) patients are not a homogeneous group: a new stratificating model in the era of targeted therapy. 48
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 48
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review 47
High blood concentration of circulating cancer stem cell-derived extracellular vesicles is associated with poor survival in advanced colorectal cancer patients 47
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 46
Totale 6.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.441
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.441
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020782 0 0 0 0 92 91 141 69 71 134 168 16
2020/2021815 122 28 153 21 51 168 33 24 58 51 30 76
2021/2022803 19 28 14 193 75 26 20 43 51 20 68 246
2022/20232.328 205 323 188 257 166 411 115 216 273 23 103 48
2023/20241.042 63 32 79 34 67 394 177 43 25 35 10 83
2024/2025990 133 454 303 68 32 0 0 0 0 0 0 0
Totale 8.210